
51 - 200 employees
Founded 2019
🧬 Biotechnology
💊 Pharmaceuticals
💰 $175.3M Post IPO equity on 2024-03
Biotechnology • Pharmaceuticals
NewAmsterdam Pharma Corporation is a clinical-stage biopharmaceutical company focused on developing therapies for cardiovascular disease and other lipid-related conditions. The company is advancing obicetrapib, a CETP inhibitor, and other programs aimed at lowering LDL-C and reducing cardiovascular risk for patients who have unmet needs despite existing lipid-lowering treatments. NewAmsterdam emphasizes science-backed development, clinical trials, and patient-focused initiatives.
🕒 June 2
Senior Director managing Finance, Legal and HR applications at NewAmsterdam Pharma. Driving business-first ethos and strategic IT solutions in pharmaceuticals.
🕒 May 27
Manager of Finance at NewAmsterdam Pharma focusing on financial management and FP&A support to enhance business performance. Collaborating with business leaders in driving strategic decision-making.
🔔 Pennsylvania – Remote
💰 $175.3M Post IPO equity on 2024-03
⏰ Full Time
🟡 Mid-level
🟠 Senior
💸 Financial Planning and Analysis (FP&A)
🕒 April 15
Director of Quality Control overseeing compliance in pharmaceutical QC tasks and vendor operations. In charge of analytical methods and regulatory submissions related to quality control.
🕒 March 25
Executive Medical Director leading clinical trials for Alzheimer's Disease at NewAmsterdam Pharma. Driving strategic objectives and collaborating with cross-functional teams to optimize product development.
🕒 March 14
Associate Director managing clinical trials at NewAmsterdam Pharma. Ensuring regulatory compliance and operational excellence in cardiovascular disease research.